Newsroom

Common acne medication may be effective in treating early-onset MS May 31, 2017

A Canadian clinical trial led by researchers at the University of Calgary’s Hotchkiss Brain Institute (HBI), at the Cumming School of Medicine (CSM), shows that minocycline, a common acne medication, can slow the progress of relapsing-remitting multiple sclerosis (MS) in people who have recently experienced their first symptoms. In addition to being an unexpected discovery – an acne drug benefitting a neurological disorder – the discovery is significant as it offers a safe and affordable treatment option for those with early onset MS.

+
Imaging technique may reduce cost, timeline of clinical trials in MS May 18, 2017

By using advanced, highly-sensitive magnetic resonance imaging (MRI) techniques, Dr. Rauscher and his team are hoping to better understand how damage occurs and how MRI can be used to monitor if new therapies are protective or have the potential to repair.

+
Researchers quantify risks associated with common MS drug May 15, 2017

The study presents novel information because no work so far has presented an extensive risk profile of the beta-interferons in the real-world setting.

+
Study of Canadian health records over 20 years suggests possibility of MS prodrome Apr 21, 2017

Study suggests possibility of MS prodrome, with increased health service use five years before the first demyelinating event.

+
Is the media landscape changing faster than science communication can keep up? Apr 4, 2017

As information-sharing has become decentralized in our digital age, are traditional approaches to science communication selling research short? A new editorial from Dr. Julie Robillard suggests that new challenges in communicating research discoveries are an opportunity for researchers to take greater initiative in sharing their work with the public, especially online.

+
Dr. Lynn Raymond
Member news: March 2017 Mar 29, 2017

Links to stories about and by members of the Djavad Mowafaghian Centre for Brain Health from February/March 2017.

+
Review of microbiome research in brain disease finds intriguing associations in an emerging field Mar 21, 2017

“Right now, there is exciting and growing evidence to suggest that the microbiota are associated with some diseases of the brain. However, more work is still needed.” says Dr. Tremlett. “One real challenge will be to prove a causative link.” 

+
Dr. Jacquie Quandt in the lab at the Centre for Brain Health
Radical approach limits disease progression in experimental models of MS Mar 13, 2017

According to new research from Dr. Jacqueline Quandt, published recently in Brain, Behaviour and Immunity, a simple compound shows promise in altering immune responses without eliminating cells and in doing so protects the cells in the nervous system and prevents the underlying neurodegeneration in models of MS.

+
New Initiative Gives Clinicians a Voice Jan 19, 2017

A new physician-engagement initiative is coming to UBC Hospital and the Djavad Mowafaghian Centre for Brain Health.

The initiative’s goal is to involve physicians working in acute care facilities as true partners in the healthcare decision-making process, and help generate improvements that will make our future BC healthcare system sustainable. Without involving physicians, achieving better patient care, and better community health at the lowest cost possible will remain elusive goals.

+
National study paints detailed picture of aging in Canada Jan 18, 2017

On the first floor of the Djavad Mowafaghian Centre for Brain Health, a massive, two decade-long project has been quietly underway for the past three years. The Vancouver Data Collection Site for the Canadian Longitudinal Study on Aging (CLSA) is based here, and Dr. Heather Stewart and her team are returning to the Centre to start the first follow-up after 18 months collecting data at SFU Surrey’s CLSA data collection site.

+

Pages